Trial Begins of Nasal Vaccine for Alzheimer Disease
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.